- Home
- MED vs PBYI Comparison
MED vs PBYI Comparison
Compare MED & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MED
- PBYI
- Stock Information
- Founded
- MED 1980
- PBYI 2010
- Country
- MED United States
- PBYI United States
- Employees
- MED N/A
- PBYI N/A
- Industry
- MED Packaged Foods
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- MED Consumer Staples
- PBYI Health Care
- Exchange
- MED Nasdaq
- PBYI Nasdaq
- Market Cap
- MED 139.0M
- PBYI 138.4M
- IPO Year
- MED N/A
- PBYI N/A
- Fundamental
- Price
- MED $12.09
- PBYI $3.03
- Analyst Decision
- MED Hold
- PBYI Strong Buy
- Analyst Count
- MED 1
- PBYI 1
- Target Price
- MED $16.50
- PBYI $7.00
- AVG Volume (30 Days)
- MED 234.4K
- PBYI 299.6K
- Earning Date
- MED 04-28-2025
- PBYI 05-01-2025
- Dividend Yield
- MED N/A
- PBYI N/A
- EPS Growth
- MED N/A
- PBYI 37.78
- EPS
- MED 0.19
- PBYI 0.62
- Revenue
- MED $602,463,000.00
- PBYI $230,468,000.00
- Revenue This Year
- MED N/A
- PBYI N/A
- Revenue Next Year
- MED N/A
- PBYI N/A
- P/E Ratio
- MED $64.53
- PBYI $4.61
- Revenue Growth
- MED N/A
- PBYI N/A
- 52 Week Low
- MED $11.57
- PBYI $2.23
- 52 Week High
- MED $36.30
- PBYI $5.26
- Technical
- Relative Strength Index (RSI)
- MED 36.50
- PBYI 51.12
- Support Level
- MED $11.57
- PBYI $2.75
- Resistance Level
- MED $13.54
- PBYI $2.99
- Average True Range (ATR)
- MED 0.62
- PBYI 0.16
- MACD
- MED -0.05
- PBYI 0.02
- Stochastic Oscillator
- MED 26.40
- PBYI 81.76
About MED MEDIFAST INC
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. OPTAVIA provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. Medifast remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.